Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Study of Oblimersen in Combination With Cisplatin and Fluorouracil in Patients With Advanced Esophageal, Gastro-Esophageal Junction and Gastric Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00064259
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:18.457559+00:00
Published At
2015-06-29T00:00:00+00:00
Record Updated At
2021-02-17
Results Posted At
2015-06-29
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Adenocarcinoma of the Esophagus", "Adenocarcinoma of the Gastroesophageal Junction", "Diffuse Adenocarcinoma of the Stomach", "Intestinal Adenocarcinoma of the Stomach", "Mixed Adenocarcinoma of the Stomach", "Recurrent Esophageal Cancer", "Recurrent Gastric Cancer", "Squamous Cell Carcinoma of the Esophagus", "Stage III Esophageal Cancer", "Stage IIIA Gastric Cancer", "Stage IIIB Gastric Cancer", "Stage IIIC Gastric Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-02-17"
protocolSection.identificationModule.nctId
"NCT00064259"
protocolSection.identificationModule.officialTitle
"A Phase I/II Study of Oblimersen in Combination With Cisplatin and Fluorouracil in Patients With Advanced Esophageal, Gastro-Esophageal Junction and Gastric Cancer"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2015-06-29"

Study condition terms

  • Adenocarcinoma of the Esophagus (protocolSection.conditionsModule.conditions)
  • Adenocarcinoma of the Gastroesophageal Junction (protocolSection.conditionsModule.conditions)
  • Diffuse Adenocarcinoma of the Stomach (protocolSection.conditionsModule.conditions)
  • Intestinal Adenocarcinoma of the Stomach (protocolSection.conditionsModule.conditions)
  • Mixed Adenocarcinoma of the Stomach (protocolSection.conditionsModule.conditions)
  • Recurrent Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Recurrent Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Squamous Cell Carcinoma of the Esophagus (protocolSection.conditionsModule.conditions)
  • Stage III Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Gastric Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.